Tritonpoint Wealth LLC Sells 96 Shares of STERIS plc (NYSE:STE)

Tritonpoint Wealth LLC lowered its position in STERIS plc (NYSE:STE) by 4.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,849 shares of the medical equipment provider’s stock after selling 96 shares during the quarter. Tritonpoint Wealth LLC’s holdings in STERIS were worth $380,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Bleakley Financial Group LLC grew its stake in shares of STERIS by 8.7% during the 3rd quarter. Bleakley Financial Group LLC now owns 1,680 shares of the medical equipment provider’s stock valued at $407,000 after purchasing an additional 134 shares during the period. Franklin Resources Inc. grew its position in STERIS by 171.2% during the third quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock valued at $191,370,000 after buying an additional 529,308 shares during the period. Assetmark Inc. grew its position in STERIS by 24.6% during the third quarter. Assetmark Inc. now owns 13,410 shares of the medical equipment provider’s stock valued at $3,252,000 after buying an additional 2,647 shares during the period. KBC Group NV increased its holdings in STERIS by 52.0% during the third quarter. KBC Group NV now owns 12,071 shares of the medical equipment provider’s stock valued at $2,928,000 after buying an additional 4,132 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in STERIS in the third quarter worth approximately $9,949,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Stock Performance

NYSE STE opened at $220.84 on Monday. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. STERIS plc has a twelve month low of $197.82 and a twelve month high of $248.24. The business has a 50-day moving average price of $212.15 and a 200-day moving average price of $224.70. The firm has a market cap of $21.80 billion, a price-to-earnings ratio of 50.42 and a beta of 0.84.

STERIS (NYSE:STE) last posted its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.02. The business had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The firm’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.03 EPS. As a group, equities research analysts predict that STERIS plc will post 9.11 EPS for the current fiscal year.

STERIS Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be issued a dividend of $0.57 per share. The ex-dividend date is Thursday, February 20th. This represents a $2.28 annualized dividend and a yield of 1.03%. STERIS’s payout ratio is 52.05%.

Insider Buying and Selling

In related news, SVP Cary L. Majors sold 1,682 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the transaction, the senior vice president now owns 11,372 shares in the company, valued at $2,471,363.04. The trade was a 12.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.14% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on STE. JMP Securities reissued a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research report on Monday, November 18th. Stephens restated an “overweight” rating and issued a $260.00 price target on shares of STERIS in a research report on Thursday, November 7th. Piper Sandler raised STERIS from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $230.00 to $260.00 in a research report on Thursday, October 24th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a report on Friday, November 8th. Finally, StockNews.com cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $262.50.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.